Search results for CD137

Anti-CD137 antibody [EPR20238] - BSA and Azide free, Abcam, AB240382

ab240382 is the carrier-free version of ab209256 . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.

CD137 / 4-1BB antibody (4B4-1) [PE], Covalab, Ref 00114401

Tecaginlimab Biosimilar – Anti-CD40 & CD137 mAb – Research Grade, ProteoGenix, PX-TA1777

Description of Tecaginlimab Biosimilar - Anti-CD40 & CD137 mAb - Research Grade Introduction Tecaginlimab Biosimilar, also known as Anti-CD40 & CD137 mAb, is a research grade antibody that has shown promising results in preclinical studies as a potential therapeutic agent. It is a biosimilar of the monoclonal antibody (mAb) tecaginlimab, which targets both CD40 and CD137, two important immune checkpoints that play a crucial role in regulating the immune response. In this article, we will discuss the structure, activity, and potential applications of Tecaginlimab Biosimilar. Structure of Tecaginlimab Biosimilar Tecaginlimab Biosimilar is a recombinant humanized monoclonal antibody, meaning that it is produced in a laboratory using genetic engineering techniques. It is composed of two heavy chains and two light chains, linked together by disulfide bonds. The heavy chains are made up of four constant regions (CH1, CH2, CH3, and CH4) and one variable region (VH), while the light chains consist of one constant region (CL) and one variable region (VL). The variable regions are responsible for binding to the target molecules, CD40 and CD137. Activity of Tecaginlimab Biosimilar CD40 and CD137 are both co-stimulatory molecules that are expressed on the surface of various immune cells, including T cells, B cells, and dendritic cells. These molecules play a critical role in activating and regulating the immune response. CD40 is involved in T cell activation, B cell differentiation, and cytokine production, while CD137 is involved in T cell proliferation and survival. Dysregulation of these pathways has been implicated in various autoimmune diseases and cancer. Tecaginlimab Biosimilar works by binding to both CD40 and CD137, blocking their interaction with their respective ligands and inhibiting their signaling pathways. This leads to a reduction in the activation and proliferation of immune cells, resulting in a dampened immune response. In addition, Tecaginlimab Biosimilar has been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC), where immune cells are activated to kill target cells that are bound by the antibody. Applications of Tecaginlimab Biosimilar The potential applications of Tecaginlimab Biosimilar are vast, given its ability to target two important immune checkpoints simultaneously. It has shown promising results in preclinical studies as a potential treatment for various autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and psoriasis. By inhibiting the activation of immune cells, Tecaginlimab Biosimilar could potentially reduce the severity of these diseases and improve patient outcomes. In addition, Tecaginlimab Biosimilar has also shown potential as a cancer therapy. CD40 and CD137 have been identified as potential targets for cancer immunotherapy, and blocking their activity with Tecaginlimab Biosimilar could enhance the anti-tumor immune response. Preclinical studies have shown that Tecaginlimab Biosimilar can inhibit tumor growth and improve survival rates in animal models of cancer. Conclusion Tecaginlimab Biosimilar, a research grade antibody targeting both CD40 and CD137, has shown great potential as a therapeutic agent in preclinical studies. Its unique structure and mechanism of action make it a promising candidate for the treatment of various autoimmune diseases and cancer. Further research and clinical trials are needed to fully understand the potential of Tecaginlimab Biosimilar and its role in improving patient outcomes.

Anti-Human CD137/TNFRSF9/4-1BB Nanobody (SAA1117), AntibodySystem, RHG11001

Anti-Mouse CD137/TNFRSF9/4-1BB Polyclonal Antibody, AntibodySystem, PMG11001

Anti-CD137 antibody [EPR23218-111] - BSA and Azide free, Abcam, AB270527

ab270527 is the carrier-free version of ab243648 . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.

Anti-CD137 antibody [EPR25096-57] (BSA and Azide free), Abcam, AB300350

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.

Anti-CD137 antibody [4B4-1] - Low endotoxin, Azide free, Abcam, AB234169

Anti-CD137 antibody [EPR17835-131] - BSA and Azide free (Capture), Abcam, AB242551

ab242551 is a BSA and Azide Free antibody supplied in an unconjugated format and it is suitable for sandwich ELISAs to quantify Mouse CD137. The recommended pair for sandwich ELISA is: Capture: ab242551, Mouse CD137 Capture Antibody (unconjugated) Detector: ab242799 , Mouse CD137 Detector Antibody (unconjugated) The reference range value is 31.25 - 2000 pg/ml. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Sandwich ELISA The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Please note that the range provided for this antibody is only an estimation based on the performance of the product using the recommended antibody pair. Performance of the antibody pair will depend on the specific characteristics of your assay. We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibody in your assay.

Anti-CD137 antibody [EPR17835-39] - BSA and Azide free (Detector), Abcam, AB242799

ab242799 is a BSA and Azide Free antibody supplied in an unconjugated format and it is suitable for sandwich ELISAs to quantify Mouse CD137. The recommended pair for sandwich ELISA is: Capture: ab242551 , Mouse CD137 Capture Antibody (unconjugated) Detector: ab242799, Mouse CD137 Detector Antibody (unconjugated) The reference range value is 31.25 - 2000 pg/ml. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Sandwich ELISA The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Please note that the range provided for this antibody is only an estimation based on the performance of the product using the recommended antibody pair. Performance of the antibody pair will depend on the specific characteristics of your assay. We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibody in your assay.